



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

1636/115
#24
Dea
8/22/02

**TRANSMITTAL AND REQUEST FOR
EXTENSION OF TIME PURSUANT TO
37 C.F.R. § 1.136(a)**

Docket Number
395/35

Application Number
09/510,562

Filing Date
February 22, 2000

Examiner
D. Guzo

Art Unit
1636

Invention Title
**METHOD FOR SCREENING FOR PROTEIN
INHIBITORS AND ACTIVATORS**

Inventor(s)
Gerard M. HOUSEY

Assistant Commissioner for Patents
Washington, D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 on Aug. 5, 2002.

By: 
Lawrence P. Casson (Reg. No. 46,606)

Sir:

Transmitted herewith is an Amendment and a Supplemental Information Disclosure Statement for entry in the above-identified application:

1. No additional claim fees are believed due.
2. Applicant respectfully requests a three-month extension of time in which to respond to the Office Action dated February 4, 2002, for which a response period expiring on May 4, 2002 was set. The extended period expires on August 5, 2002. Please charge payment of the 37 C.F.R. § 1.136(a) extension fee of **\$920.00** to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**.
3. Enclosed is an Information Disclosure Statement and modified PTO Form 1449. Applicant elects to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c). Please charge payment of the **\$180.00** fee to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**.
4. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**:
 - A. Any additional filing fees required under 37 C.F.R. § 1.16;
 - B. Any additional patent application processing fees under 37 C.F.R. § 1.17;
 - C. Any additional patent issue fees under 37 C.F.R. § 1.18;
 - D. Any additional document supply fees under 37 C.F.R. § 1.19;
 - E. Any additional post-patent processing fees under 37 C.F.R. § 1.20; or
 - F. Any additional miscellaneous fees under 37 C.F.R. § 1.21.
5. A copy of this letter is enclosed.

RECEIVED

AUG 19 2002

TECH CENTER 1600/2900

Dated: August 5, 2002

By: 
Lawrence P. Casson (Reg. No. 46,606)
KENYON & KENYON

One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)

09/05/2002 MICHAMM1 00000058 110600 09510562

01 FC:117 920.00 CH



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 19 2002

TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
395/35

Application Number
09/510,562

Filing Date
February 22, 2000

Examiner
D. Guzo

Art Unit
1636

Invention Title
**METHOD OF SCREENING FOR PROTEIN
INHIBITORS AND ACTIVATORS**

Inventor(s)
Gerard M. HOUSEY

Address to:
Assistant Commissioner for Patents
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on Aug. 5, 2002.

By: 
Lawrence P. Casson (Reg. No. 46,606)

SIR:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97(c) and 1.98 and M.P.E.P. § 609, Applicant hereby brings the references listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The references disclosed herein and on the attached modified PTO Form No. 1449 have been brought to the attention of the Applicant in litigation of U.S. Patents that issued from one or more applications to which the instant application claims priority under 35 U.S.C. § 120.
3. Pursuant to the aforementioned litigation, Applicant further discloses:
 - (1) Expert Report of Igor B. Roninson, Ph.D.
 - (2) Expert Report of Marius Ueffing, Ph.D.
4. Applicants also bring to Examiner's attention the following U.S. Patent Application:
U.S. Ser. No. 08/953,550
U.S. Ser. No. 08/953,550 was involved in Interference No. 104,347 with three of the Applicant's issued patents. The interference was decided by the Board of Patent Appeals and Interferences in favor of the Applicant.
5. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).


08/15/2002 WFO/AMM1 00000058 110600 09510552

02 F0403 100.00 CH

6. Copies of all of the references cited herein and on the enclosed modified PTO Form No. 1449 have been provided to the Examiner in copending U.S. Ser. No. 09/510,554. In accordance with the previous Examiner's preference, additional copies are not being sent with this IDS, but will be provided upon the Examiner's request.

Dated: August 5, 2002

By:


Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

RECEIVED
TECH CENTER 1800/2900
02 OCT -1 AM 11:46

#27

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
395/35

Application Number
09/510,562

Filing Date
February 22, 2000

Examiner
D. Guzo

Art Unit
1636

Invention Title
METHOD OF SCREENING FOR PROTEIN
INHIBITORS AND ACTIVATORS

Inventor(s)
Gerard M. HOUSEY

RECEIVED

OCT 04 2002

Address to:
Assistant Commissioner for Patents
Washington D.C. 20231


TECH CENTER 1600/2900

SIR:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97(c) and 1.98 and M.P.E.P. § 609, Applicant hereby brings the references listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The references disclosed herein have been brought to the attention of the Applicant in litigation of U.S. Patents that issued from one or more applications to which the instant application claims priority under 35 U.S.C. § 120.
3. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
4. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.17(p) (submission of an information disclosure statement under § 1.97(c)) fee of **\$180.00** and any additional fees that may be required to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**.

Dated: September 30, 2002

By:



Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)